Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Posts Sharp Q4, FY2017 Revenue Increase

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics on Thursday posted a 427 percent jump in fourth quarter revenues, an increase driven by partnership revenues.

For the three-month period ended Dec. 31, 2017, HTG's revenues grew to $7.9 million from $1.5 million in the same period a year earlier. The company attributed the bulk of that growth to its various collaborations, which include an ongoing project with Qiagen to develop next-generation sequencing gene expression profiling assays for multiple undisclosed cancer therapies and a recently expanded companion diagnostic alliance with Merck KGaA.

The company's fourth quarter net loss fell 67 percent to $1.9 million, or $.15 per share, from $5.7 million, or $.76 per share, a year earlier. 

HTG's fourth quarter R&D spending increased to $3.6 million from $1.4 million, while its SG&A costs edged up to $4.6 million from $4.1 million.

For the full year, HTG's revenues rose 190 percent to $14.8 million from $5.1 million in 2016, while its net loss fell 27 percent to $19 million, or $1.79 per share, from $26 million, or $3.66 per share.

Its R&D spending during 2017 climbed to $10 million from $7.9 million, and SG&A expenses edged up to $17.5 million from $17.4 million.

At the end of 2017, HTG had cash and cash equivalents totaling $10 million. In January, the firm raised $40.4 million through a public offering.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.